#United States #gene therapy #Cell Therapy #Falls Church #Longitude Health

Longitude Health Partners with Five Health Systems for Cell and Gene Therapy Development

Longitude Health has just announced a significant collaboration with five prominent health systems: Michigan Medicine, Novant Health, Baylor Scott & White Health, Memorial Hermann Health System, and Providence. This pivotal partnership centers on the development of Longitude Cell and Gene Therapy (CGT), which aims to streamline and enhance the effectiveness of cell and gene therapy programs within these health systems.

Addressing Complex Challenges in Advanced Therapies

As the adoption of cell and gene therapies expands across different medical fields, health systems face a myriad of challenges. These include navigating complex workflows related to prior authorizations, reimbursement processes, care coordination, logistics at treatment sites, tracking patient outcomes, and ensuring long-term follow-ups. Longitude CGT seeks to develop technology solutions that simplify these procedures and improve operational flow, ultimately benefiting the patient experience.

Sinthu Sinnadurai, President of Longitude CGT, emphasized the significant medical potential of cell and gene therapies, stating, "These therapies hold great promise in modern medicine, but they also introduce substantial operational and financial complexities for healthcare providers." The collaboration with these five health systems is expected to yield practical solutions that address the specific needs of care delivery in this fast-evolving sector.

Contributions from Partner Health Systems

The member health systems will leverage their extensive clinical, operational, financial, and technical expertise to develop solutions that are tailored to meet the real-world requirements of organizations providing advanced therapies. By validating workflows and identifying avenues for improvement, this alliance will enhance the effectiveness of the platform intended for delivering these therapies.

Dana Habers, Chief Innovations Officer at Michigan Medicine, noted, "Our involvement ensures that the design of Longitude CGT is informed by actual patient cases and the day-to-day needs of health systems-operation." This emphasis on pragmatic improvements is central to fostering better care coordination and increasing patient access.

A Commitment to Sustainable Delivery Models

The formation of this partnership underscores a collective commitment to innovating the delivery of cell and gene therapies. By integrating health system knowledge with technological advancements and collaborative design approaches, Longitude CGT aims to eliminate fragmentation in treatment delivery, optimize operational performance, and broaden access to these critical therapies for patients in need.

Dr. David Rizzieri, Senior Vice President and Physician-in-Chief of Novant Health Cancer Institute, remarked, "These advanced therapies are revolutionizing treatment paradigms, particularly for cancer and autoimmune diseases. It is essential to mitigate the administrative obstacles associated with their implementation to allow healthcare institutions to keep pace with advancements and ensure safe administration of these therapies beyond specialized centers."

About Longitude Health

Founded by prominent health systems aiming to transform the healthcare landscape, Longitude Health is dedicated to crafting bold and innovative solutions that drive meaningful change for patients and their communities. The collaborative is actively engaged in building and scaling various capabilities designed to enhance performance, lower costs, and tackle pressing operational issues within healthcare. The member systems, including Baylor Scott & White Health, Memorial Hermann Health System, Michigan Medicine, Novant Health, and Providence, represent a robust network committed to advancing healthcare.

For more information about Longitude Health and their initiatives, visit Longitude Health.